Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of MGL-3196 in heterozygous familial hypercholesterolemia
2016-002315-17Phase 2Completed
- Sponsor
- Madrigal Pharmaceuticals
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of resmetirom in heterozygous familial hypercholesterolemia (HeFH) (3 arms), sponsored by Madrigal Pharmaceuticals. Primary endpoint: Percent change from baseline in low density lipoprotein cholesterol. Started Nov 2016; status: completed.
02
Drugs
resmetirom
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2016-002315-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002315-17.